Needham & Company on Teva Pharma (TEVA): Potential Near-Term Pivot Points Could Bump Up Short-Term Volatility; Underlying Fundamentals Unchanged
Tweet Send to a Friend
Needham & Company maintains a 'Strong Buy' on Teva Pharma (NASDAQ: TEVA), PT $65.
Needham analyst says, "While Teva shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "While Teva shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
